Terms: = Brain cancer AND TRD AND Treatment
18 results:
1. Spectral signatures of psilocybin, lysergic acid diethylamide (LSD) and ketamine in healthy volunteers and persons with major depressive disorder and treatment-resistant depression: A systematic review.
Le GH; Wong S; Badulescu S; Au H; Di Vincenzo JD; Gill H; Phan L; Rhee TG; Ho R; Teopiz KM; Kwan ATH; Rosenblat JD; Mansur RB; McIntyre RS
J Affect Disord; 2024 Jun; 355():342-354. PubMed ID: 38570038
[TBL] [Abstract] [Full Text] [Related]
2. A randomized sham-controlled trial of high-dosage accelerated intermittent theta burst rTMS in major depression: study protocol.
Goodman MS; Vila-Rodriguez F; Barwick M; Burke MJ; Downar J; Hunter J; Kaster TS; Knyahnytska Y; Kurdyak P; Maunder R; Thorpe K; Trevizol AP; Voineskos D; Zhang W; Blumberger DM
BMC Psychiatry; 2024 Jan; 24(1):28. PubMed ID: 38191370
[TBL] [Abstract] [Full Text] [Related]
3. The rapid antidepressant effectiveness of repeated dose of intravenous ketamine and intranasal esketamine: A post-hoc analysis of pooled real-world data.
d'Andrea G; Pettorruso M; Di Lorenzo G; Rhee TG; Chiappini S; Carullo R; Barlati S; Zanardi R; Rosso G; Di Nicola M; Andriola I; Marcatili M; Clerici M; Dell'Osso BM; Sensi SL; Mansur RB; Rosenblat JD; Martinotti G; McIntyre RS
J Affect Disord; 2024 Mar; 348():314-322. PubMed ID: 38145840
[TBL] [Abstract] [Full Text] [Related]
4. Real-world effectiveness of repeated intravenous ketamine infusions for treatment-resistant depression in transitional age youth.
Chisamore N; Danayan K; Rodrigues NB; Di Vincenzo JD; Meshkat S; Doyle Z; Mansur R; Phan L; Fancy F; Chau E; Tabassum A; Kratiuk K; Arekapudi A; McIntyre RS; Rosenblat JD
J Psychopharmacol; 2023 Aug; 37(8):775-783. PubMed ID: 37194253
[TBL] [Abstract] [Full Text] [Related]
5. The Impact of
Santos M; Lima L; Carvalho S; Mota-Pereira J; Pimentel P; Maia D; Correia D; Barroso MF; Gomes S; Cruz A; Medeiros R
Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047730
[TBL] [Abstract] [Full Text] [Related]
6. Real world effectiveness of repeated ketamine infusions for treatment-resistant depression with comorbid borderline personality disorder.
Danayan K; Chisamore N; Rodrigues NB; Vincenzo JDD; Meshkat S; Doyle Z; Mansur R; Phan L; Fancy F; Chau E; Tabassum A; Kratiuk K; Arekapudi A; Teopiz KM; McIntyre RS; Rosenblat JD
Psychiatry Res; 2023 May; 323():115133. PubMed ID: 36889160
[TBL] [Abstract] [Full Text] [Related]
7. The association between stage of treatment-resistant depression and clinical utility of ketamine/esketamine: A systematic review.
Levinta A; Meshkat S; McIntyre RS; Ho C; Lui LMW; Lee Y; Mansur RB; Teopiz KM; Rodrigues NB; Di Vincenzo JD; Ceban F; Rosenblat JD
J Affect Disord; 2022 Dec; 318():139-149. PubMed ID: 36049604
[TBL] [Abstract] [Full Text] [Related]
8. Transcriptomic signatures of psychomotor slowing in peripheral blood of depressed patients: evidence for immunometabolic reprogramming.
Bekhbat M; Goldsmith DR; Woolwine BJ; Haroon E; Miller AH; Felger JC
Mol Psychiatry; 2021 Dec; 26(12):7384-7392. PubMed ID: 34535767
[TBL] [Abstract] [Full Text] [Related]
9. A narrative review on invasive brain stimulation for treatment-resistant depression.
Dandekar MP; Diaz AP; Rahman Z; Silva RH; Nahas Z; Aaronson S; Selvaraj S; Fenoy AJ; Sanches M; Soares JC; Riva-Posse P; Quevedo J
Braz J Psychiatry; 2022; 44(3):317-330. PubMed ID: 34468549
[TBL] [Abstract] [Full Text] [Related]
10. The effect of single administration of intravenous ketamine augmentation on suicidal ideation in treatment-resistant unipolar depression: Results from a randomized double-blind study.
Feeney A; Hock RS; Freeman MP; Flynn M; Hoeppner B; Iosifescu DV; Trivedi MH; Sanacora G; Mathew SJ; Debattista C; Ionescu DF; Fava M; Papakostas GI
Eur Neuropsychopharmacol; 2021 Aug; 49():122-132. PubMed ID: 34090255
[TBL] [Abstract] [Full Text] [Related]
11. The effectiveness of repeated intravenous ketamine on depressive symptoms, suicidal ideation and functional disability in adults with major depressive disorder and bipolar disorder: Results from the Canadian Rapid treatment Center of Excellence.
McIntyre RS; Rodrigues NB; Lee Y; Lipsitz O; Subramaniapillai M; Gill H; Nasri F; Majeed A; Lui LMW; Senyk O; Phan L; Carvalho IP; Siegel A; Mansur RB; Brietzke E; Kratiuk K; Arekapudi AK; Abrishami A; Chau EH; Szpejda W; Rosenblat JD
J Affect Disord; 2020 Sep; 274():903-910. PubMed ID: 32664031
[TBL] [Abstract] [Full Text] [Related]
12. Exploring cortical predictors of clinical response to electroconvulsive therapy in major depression.
Schmitgen MM; Kubera KM; Depping MS; Nolte HM; Hirjak D; Hofer S; Hasenkamp JH; Seidl U; Stieltjes B; Maier-Hein KH; Sambataro F; Sartorius A; Thomann PA; Wolf RC
Eur Arch Psychiatry Clin Neurosci; 2020 Mar; 270(2):253-261. PubMed ID: 31278421
[TBL] [Abstract] [Full Text] [Related]
13. Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (trd).
Fava M; Freeman MP; Flynn M; Judge H; Hoeppner BB; Cusin C; Ionescu DF; Mathew SJ; Chang LC; Iosifescu DV; Murrough J; Debattista C; Schatzberg AF; Trivedi MH; Jha MK; Sanacora G; Wilkinson ST; Papakostas GI
Mol Psychiatry; 2020 Jul; 25(7):1592-1603. PubMed ID: 30283029
[TBL] [Abstract] [Full Text] [Related]
14. Bilateral Repetitive Transcranial Magnetic Stimulation Decreases Suicidal Ideation in Depression.
Weissman CR; Blumberger DM; Brown PE; Isserles M; Rajji TK; Downar J; Mulsant BH; Fitzgerald PB; Daskalakis ZJ
J Clin Psychiatry; 2018; 79(3):. PubMed ID: 29701939
[TBL] [Abstract] [Full Text] [Related]
15. Unilateral and bilateral MRI-targeted repetitive transcranial magnetic stimulation for treatment-resistant depression: a randomized controlled study.
Blumberger DM; Maller JJ; Thomson L; Mulsant BH; Rajji TK; Maher M; Brown PE; Downar J; Vila-Rodriguez F; Fitzgerald PB; Daskalakis ZJ
J Psychiatry Neurosci; 2016 Jun; 41(4):E58-66. PubMed ID: 27269205
[TBL] [Abstract] [Full Text] [Related]
16. The role of IL18-607C>A and IL18-137G>C promoter polymorphisms in antidepressant treatment phenotypes: A preliminary report.
Santos M; Carvalho S; Lima L; Mota-Pereira J; Pimentel P; Maia D; Correia D; Gomes S; Cruz A; Medeiros R
Neurosci Lett; 2016 May; 622():107-12. PubMed ID: 27001087
[TBL] [Abstract] [Full Text] [Related]
17. Risk of treatment related death and febrile neutropaenia with first line palliative chemotherapy for de novo metastatic breast cancer in clinical practice in a middle resource country.
Phua CE; Tang WH; Yusof MM; Saad M; Alip A; See MH; Taib NA
Asian Pac J Cancer Prev; 2014; 15(23):10263-6. PubMed ID: 25556458
[TBL] [Abstract] [Full Text] [Related]
18. Taurolidine--a new drug with anti-tumor and anti-angiogenic effects.
Jacobi CA; Menenakos C; Braumann C
Anticancer Drugs; 2005 Oct; 16(9):917-21. PubMed ID: 16162968
[TBL] [Abstract] [Full Text] [Related]
